Sonoma Pharmaceuticals (SNOA) Competitors $5.09 +0.03 (+0.59%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.04 -0.04 (-0.88%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. ESLA, SCYX, RNXT, AKTX, CLSD, MURA, BTAI, MAAQ, SNYR, and DYAIShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Estrella Immunopharma (ESLA), SCYNEXIS (SCYX), RenovoRx (RNXT), Akari Therapeutics (AKTX), Clearside Biomedical (CLSD), Mural Oncology (MURA), BioXcel Therapeutics (BTAI), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Estrella Immunopharma SCYNEXIS RenovoRx Akari Therapeutics Clearside Biomedical Mural Oncology BioXcel Therapeutics Mana Capital Acquisition Synergy CHC Dyadic International Estrella Immunopharma (NASDAQ:ESLA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Does the media prefer ESLA or SNOA? In the previous week, Estrella Immunopharma had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.00 beat Estrella Immunopharma's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Neutral Sonoma Pharmaceuticals Positive Which has more volatility and risk, ESLA or SNOA? Estrella Immunopharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Is ESLA or SNOA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -23.87%. Sonoma Pharmaceuticals' return on equity of -50.00% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -358.54% Sonoma Pharmaceuticals -23.87%-50.00%-16.79% Do analysts recommend ESLA or SNOA? Estrella Immunopharma presently has a consensus target price of $16.00, indicating a potential upside of 1,549.65%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Estrella Immunopharma is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, ESLA or SNOA? Estrella Immunopharma has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/A-$0.26-3.73Sonoma Pharmaceuticals$14.29M0.58-$3.46M-$2.46-2.07 Do institutionals & insiders believe in ESLA or SNOA? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryEstrella Immunopharma and Sonoma Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.31M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-2.0722.6131.1026.05Price / Sales0.58550.49432.51103.82Price / CashN/A180.4637.7358.48Price / Book2.065.939.536.61Net Income-$3.46M$31.83M$3.26B$265.56M7 Day Performance-4.86%1.89%2.10%1.97%1 Month Performance37.20%1.33%2.81%-0.36%1 Year Performance2,003.31%8.84%30.56%19.03% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma PharmaceuticalsN/A$5.09+0.6%N/A+2,152.2%$8.31M$14.29M-2.07180Gap DownESLAEstrella Immunopharma2.3011 of 5 stars$0.94+2.7%$16.00+1,611.2%-26.5%$34.66MN/A-3.60N/ASCYXSCYNEXIS1.0268 of 5 stars$0.83+2.8%N/A-51.4%$34.58M$3.75M-2.0660News CoverageAnalyst RevisionRNXTRenovoRx2.9077 of 5 stars$0.94+0.1%$7.25+670.5%-3.1%$34.41M$40K-2.486News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionAKTXAkari Therapeutics2.4143 of 5 stars$1.00flat$5.00+400.0%-75.1%$32.18MN/A0.009CLSDClearside Biomedical1.8858 of 5 stars$0.40-5.8%$4.20+947.4%-59.7%$31.48M$4.17M-1.0830MURAMural Oncology3.0017 of 5 stars$1.77-2.7%$12.00+578.0%-36.6%$30.84MN/A-0.21119BTAIBioXcel Therapeutics4.5816 of 5 stars$4.95-12.8%$39.75+703.7%-52.3%$29.72M$2.27M-0.3990Short Interest ↓MAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+727.6%$29.49MN/A0.001SNYRSynergy CHC4.2786 of 5 stars$3.18-8.6%$10.00+214.5%N/A$29.24M$33.70M8.3740DYAIDyadic International3.4956 of 5 stars$0.80+0.5%$6.00+650.9%-38.0%$28.92M$3.49M-4.217Gap Up Related Companies and Tools Related Companies Estrella Immunopharma Competitors SCYNEXIS Competitors RenovoRx Competitors Akari Therapeutics Competitors Clearside Biomedical Competitors Mural Oncology Competitors BioXcel Therapeutics Competitors Mana Capital Acquisition Competitors Synergy CHC Competitors Dyadic International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access